Item 7.01. Regulation FD.

On January 25, 2021, Abeona Therapeutics Inc. issued a press release entitled "Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)." The full text of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No.   Description
99.1            Press release dated January 25, 2021, entitled "Abeona
              Therapeutics Announces Successful Type B Meeting with FDA for
              Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic
              Epidermolysis Bullosa (RDEB)."
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses